Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On Aug.</li><li>7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update.</li><li>The company is approaching a potentially transformative period as two Phase 2 studies of (Z)-endoxifen are expected to produce data by year-end.</li></ul>

On Aug.7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update.The company is approaching a potentially transformative period as two Phase 2 studies of (Z)-endoxifen are expected to produce data by year-end.

ATOS: Multiple Catalysts Converge in 2H26

<ul><li>In June 2026, Atossa Therapeutics, Inc. (ATOS) announced the closing of a registered direct offering of 1,363,637 shares of its common stock and Series A and B warrants to purchase up to 1,363,637 shares of common stock each.</li><li>Gross proceeds from the offering were approximately $4.5 million, with the potential for approximately $12 million if all warrants were fully exercised on a cash basis.</li><li> In June 2026, the company presented two abstracts featuring (Z)-endoxifen at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.</li></ul>

In June 2026, Atossa Therapeutics, Inc. (ATOS) announced the closing of a registered direct offering of 1,363,637 shares of its common stock and Series A and B warrants to purchase up to 1,363,637 shares of common stock each.Gross proceeds from the offering were approximately $4.5 million, with the potential for approximately $12 million if all warrants were fully exercised on a cash basis. In June 2026, the company presented two abstracts featuring (Z)-endoxifen at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.

ATOS: Raises up to 16.5 Million in Registered Direct Offering

<ul><li>We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00.</li><li>Atossa is a clinical-stage biopharmaceutical company focused on rare diseases and oncology with a significant unmet need.</li><li>The lead development compound is (Z)-endoxifen, which is being advanced across multiple indications, including McCune-Albright Syndrome (MAS), breast cancer, and other endocrine-driven conditions.</li></ul>

We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00.Atossa is a clinical-stage biopharmaceutical company focused on rare diseases and oncology with a significant unmet need.The lead development compound is (Z)-endoxifen, which is being advanced across multiple indications, including McCune-Albright Syndrome (MAS), breast cancer, and other endocrine-driven conditions.

ATOS:  Initiating Coverage of Atossa Therapeutics  Endoxifen's Expanding Opportunity from Oncology to Orphan Disease

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) were able to shrug off recent news of a more contagious Covid variant that popped-up in the UK. Additionally, Covid fears have done nothing to derail ongoing positive market dynamics. As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying opportunity. Actionable Themes in today's report: Services, Technology, Manufacturing, and Materials.</p>

Broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) were able to shrug off recent news of a more contagious Covid variant that popped-up in the UK. Additionally, Covid fears have done nothing to derail ongoing positive market dynamics. As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying opportunity. Actionable Themes in today's report: Services, Technology, Manufacturing, and Materials.

Global Equity Strategy: Support Levels Holding; Bullish Outlook Intact

United States

Atossa Therapeutics, Inc. operates as a biopharmaceutical company. The Company discovers proprietary therapeutics and delivery methods for breast cancer and other related conditions. Atossa Therapeutics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Atossa Therapeutics (ATOS US)

ATOS: Multiple Catalysts Converge in 2H26

On Aug. 7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update. The...

Zacks Small Cap Research

ATOS: Raises up to 16.5 Million in Registered Direct Offering

In June 2026, Atossa Therapeutics, Inc. (ATOS) announced the closing of a registered direct offering of 1,363,637 shares of its common stock and...

Zacks Small Cap Research

ATOS: Initiating Coverage of Atossa Therapeutics Endoxifen's Expanding Opportunity from Oncology to Orphan Disease

We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company...

Zacks Small Cap Research

Atossa Therapeutics Inc - May 13, 2026

We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company...

Zacks Small Cap Research

Global Equity Strategy: Support Levels Holding; Bullish Outlook Intact

As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)